source
- Industry and rare disease groups call for more transparency in FDA voucher pilotThe pharmaceutical industry and rare‑disease advocacy groups have voiced concerns about the Commissioner's National Priority Voucher pilot program. Stakeholders say the program lacks transparency…
- House Appropriations Committee urges FDA to accelerate IND approvals for clinical trialsThe House Appropriations Committee issued a directive to the Food and Drug Administration, calling for reforms to speed up the Investigational New Drug (IND) sign-off process for new clinical trial…